Advertisement
Julie Zhang
Reporter, Business
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Julie Zhang joined SCMP in 2025 as a business reporter. She was formerly with China Daily Hong Kong Edition for over five years, covering corporate earnings, IPOs, financial regulations, ESG, cryptocurrency and property markets. Her reporting garnered multiple Hong Kong News Awards and Hang Seng University's Business Journalism Award.
Areas of Expertise:
Corporate finance, IPOSLanguages Spoken:
Cantonese, English, Mandarin
Genscript posted adjusted net profit of US$62.52 million for the six months ended June 30, a 203 per cent year-on-year surge.
Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.
China is throwing the power of the state behind efforts to overtake Elon Musk in a vital frontier technology: brain-computer interfaces.
Bullion forecasts have softened, LBMA’s survey shows, despite the World Gold Council reporting unprecedented demand in second quarter.
Advertisement
The technology – which allows patients to control digital devices using their thoughts – can be implanted like a stent in just a few minutes.
The foreign investments can help Chinese companies grow and compete on the global stage, according to Citic Securities.
Hong Kong Investment Corporation is stepping up its efforts to position itself amid Beijing’s challenge to US pharmaceutical dominance.
Rising demand from central banks to drive a rebound despite temporary downside pressure from energy and interest rates, Goldman Sachs says.
The number of new accounts opened on the Shanghai Stock Exchange was down 7 per cent month on month.
Strong orders for weight-loss and diabetes treatments drive firm’s growth, despite being caught up in US efforts to curb China’s ambitions.
National Social Security Fund increases onshore stock stakes, targeting tech as state pension returns hit 5.76 per cent.
Pharmaceutical contractor’s GLP-1 programmes and surging stock gains have made it a magnet for global investors.
Chinese mutual funds shifted focus amid market volatility, cutting their share of Hong Kong stocks to 23.3 per cent in the second quarter.
Analysts say that China’s pivot from generics to innovative drugs means the industry is less exposed to US levies.
Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.
Axiom Biosciences founder says Hong Kong investors show greater maturity than Nasdaq in handling biotech companies.
Home-grown therapies account for 80 per cent of approvals in first six months of the year.
Chinese gold producers, after a buying spree for mines abroad, are cashing in as the metal’s price goes sky-high.
Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply.
Lab-grown diamond maker Power Diamond sees profits triple as De Beers warns of ‘protracted’ challenges in natural stone market.
Soaring profits at Tianqi and Ganfeng highlight how global demand for energy independence is powering China’s lithium edge.
Chinese medical device companies eye Europe for relief from hospital probes at home while navigating protectionism overseas.
China develops 30 per cent of new therapies worldwide as it rises to the top tier in innovation efficiency, drug supervision official says.
Bourse expected to see influx of international issuers in year’s second half, led by consumer goods and services companies, according to PwC.
Quota expanded to 500 billion yuan from Friday, with tenor increased to two to three years, up from one.
Global gold market trading volumes averaged a record US$488 billion per day during the first half of the year.
The rapid development of China’s RAS-targeted cancer drugs could reshape global oncology and unlock the country’s undervalued biotech firms.
Chief Executive John Lee announces ‘milestone’ for city’s gold trading ecosystem at Hong Kong FIC & Bond Connect Summit.
Hong Kong Monetary Authority widens scope of yuan finance to solidify status as ‘offshore laboratory’ for currency amid de-dollarisiation trend.
